Arbutus Biopharma
ABUS
ABUS
48 hedge funds and large institutions have $26.5M invested in Arbutus Biopharma in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
48
Holders Change
-11
Holders Change %
-18.64%
% of All Funds
1.06%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
9
Increased
17
Reduced
10
Closed
18
Calls
$749K
Puts
$13K
Net Calls
+$736K
Net Calls Change
+$235K
Top Buyers
1 |
CAC
Cowen and Company
New York
|
+$3.44M |
2 |
Citadel Advisors
Miami,
Florida
|
+$2.45M |
3 |
Goldman Sachs
New York
|
+$1.87M |
4 |
RI
RTW Investments
New York
|
+$1.21M |
5 |
HP
Hound Partners
New York
|
+$580K |
Top Sellers
1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$10.3M |
2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.27M |
3 |
Jennison Associates
New York
|
-$2.61M |
4 |
Norges Bank
Oslo,
Norway
|
-$1.03M |
5 |
Bank of New York Mellon
New York
|
-$713K |